GBT to Announce Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
July 27 2021 - 8:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today
announced that it will report second quarter 2021 financial results
on Tuesday, August 3, 2021, after U.S. financial markets close.
Management will host a conference call on Tuesday, August 3,
2021, at 4:30 p.m. ET to discuss second quarter 2021 financial
results and to provide a general business update. To participate in
the conference call, please dial 877-407-3982 (domestic) or +1
201-493-6780 (international). A live audio webcast of the
conference call can be accessed on GBT’s website at www.gbt.com
under the Investors section. An archived audio webcast will be
available for one month following the event.
About Global Blood TherapeuticsGlobal Blood
Therapeutics (GBT) is a biopharmaceutical company dedicated to
the discovery, development, and delivery of life-changing
treatments that provide hope to underserved patient communities.
Founded in 2011, GBT is delivering on its goal to transform the
treatment and care of sickle cell disease (SCD), a lifelong,
devastating inherited blood disorder. The company has introduced
Oxbryta® (voxelotor) tablets, the first FDA-approved treatment
that directly inhibits sickle hemoglobin polymerization, the root
cause of red blood cell sickling in SCD. GBT is also advancing its
pipeline program in SCD with inclacumab, a P-selectin inhibitor in
Phase 3 development to address pain crises associated with the
disease, and GBT021601 (GBT601), the company’s next generation
hemoglobin S polymerization inhibitor. In addition, GBT’s drug
discovery teams are working on new targets to develop the next wave
of potential treatments for SCD. To learn more, please
visit www.gbt.com and follow the company on
Twitter @GBT_news.
Contact:Steven Immergut
(media)650-410-3258simmergut@gbt.com
Courtney Roberts (investors)650-351-7881croberts@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2023 to Apr 2024